[클리니컬 히스토리] LG화학, 통풍신약 中 3상 진입…안전 경로 선택

LG Chem's strategic pivot from global clinical trials to China-focused development for Tigulixostat demonstrates a pragmatic approach to reduce development costs and risks while accessing a massive market of 25.56 million gout patients. By adopting a licensing-out model with a local partner, the company minimizes financial exposure while preserving commercialization upside, reflecting an emerging industry trend away from costly global programs. This case illustrates how biotech companies increasingly prioritize de-risked, region-specific pathways to achieve commercial viability in competitive markets.